A multiple dose, double blind, double-dummy, two-week 3 way cross-over, placebo-controlled clinical trial to assess the efficacy and safety of twice daily inhaled Aclidinium-bromide 400 µg compared to placebo and to an active comparator in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD)

Trial Profile

A multiple dose, double blind, double-dummy, two-week 3 way cross-over, placebo-controlled clinical trial to assess the efficacy and safety of twice daily inhaled Aclidinium-bromide 400 µg compared to placebo and to an active comparator in patients with stable moderate to severe chronic obstructive pulmonary disease (COPD)

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Nov 2016

At a glance

  • Drugs Aclidinium bromide (Primary) ; Tiotropium bromide
  • Indications Chronic obstructive pulmonary disease
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 21 Apr 2012 New source identified and integrated (European Clinical Trials Database; EudraCT2008-006886-10).
    • 08 Sep 2011 Results published in the Chest.
    • 22 Sep 2010 Results were presented at the 20th Annual Congress of the European Respiratory Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top